Coverage with Evidence Development

Medicare reimburses for the Aurix® System when physicians agree to collect their patients’ treatment data for Medicare. This is called Coverage with Evidence Development (CED). CED is a program that Medicare uses to provide coverage††for items or services while building additional evidence about how patients benefit from these products. It also provides qualified patients with access to an innovative and effective Wound Management therapy.

As part of this data collection program, the following types of wounds are covered:

  • Diabetic foot ulcers
  • Venous ulcers
  • Pressure ulcers

Participation Information for Physician & Healthcare Professionals

If you are a health care professional, a representative from Nuo Therapeutics, Inc., the manufacturer of Aurix, can explain the data collection protocols and will support you from initial enrollment through treatment, documentation, and claims submission. Please contact us for more information on the CED protocol and Medicare reporting requirements.

Coverage under private insurance and Medicaid is currently determined on a case-by-case basis.